These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30995705)

  • 1. Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance.
    Kennedy DC
    Duke Law J; 2019 Apr; 68(7):1433-68. PubMed ID: 30995705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

  • 5. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 6. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of
    Carson P; Cade A
    Pharm Pat Anal; 2019 May; 8(3):65-70. PubMed ID: 31179899
    [No Abstract]   [Full Text] [Related]  

  • 8. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
    Darrow JJ; Beall RF; Kesselheim AS
    Appl Health Econ Health Policy; 2019 Feb; 17(1):47-54. PubMed ID: 30141133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 11. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 13. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
    Genieser LH; McCann CE
    Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
    Wolff ME
    J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 16. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 17. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
    Effingham AM
    Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
    [No Abstract]   [Full Text] [Related]  

  • 18. How the new Patent Trial and Appeal Board rules impact the practice of inter partes reviews.
    Hsing BC; French-Brown W
    Pharm Pat Anal; 2016 Sep; 5(5):281-3. PubMed ID: 27573095
    [No Abstract]   [Full Text] [Related]  

  • 19. USA-Morocco deal may extend drug patents to 30 years.
    Ahmad K
    Lancet; 2003 Dec; 362(9399):1904. PubMed ID: 14672079
    [No Abstract]   [Full Text] [Related]  

  • 20. How would patent reform legislation in the United States impact the pharmaceutical industry?
    Williams AW
    Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.